Price
No data yet.
Social Signal Score
Analyst Ratings
45 analystsRevenue
$4.43B+89.39%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ari Bousbib
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 94,000
- Beta
- 1.16
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 2.26
Financials
Revenue
$4.43B+89.4%Net Income
$350.00MEBITDA
$952.00M+199.8%Free Cash Flow
$667.00M+84.7%EPS (diluted)
$2.10Shares Outstanding (diluted)
167.00M-30.1%Operating Expenses
$569.00MCash & Debt
$2.42BReturn of Capital
$0.00Revenue by Segment (annual)
$16.31BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $16.31B | $1.36B | $7.91 |
| 2024 | $15.40B | $1.37B | $7.57 |
| 2023 | $14.98B | $1.36B | $7.39 |
| 2022 | $14.41B | $1.09B | $5.82 |
| 2021 | $13.87B | $966.00M | $5.05 |
| 2020 | $11.36B | $279.00M | $1.46 |
| 2019 | $11.09B | $191.00M | $0.98 |
| 2018 | $10.41B | $259.00M | $1.27 |
| 2017 | $9.70B | $1.31B | $6.01 |
| 2016 | $6.82B | $115.00M | $0.77 |
| 2015 | $5.74B | $387.20M | $3.15 |
| 2014 | $5.46B | $356.38M | $2.78 |
| 2013 | $5.10B | $226.59M | $1.83 |
| 2012 | $4.87B | $177.55M | $1.42 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from IQV's reported EPS growth of 14.1% a year over 13 years.
- EPS in 5 years
- $15.30
- Implied price
- $428.40
- Return from $264.73
- 10.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $212.99 — -19.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 20 | 24 | 28 | 32 | 36 |
|---|---|---|---|---|---|
| 4.1% | -6.1% | -2.6% | 0.5% | 3.2% | 5.6% |
| 9.1% | -1.6% | 2.1% | 5.3% | 8.1% | 10.7% |
| 14.1% | 2.9% | 6.8% | 10.1% | 13.1% | 15.8% |
| 19.1% | 7.5% | 11.4% | 14.9% | 18.0% | 20.9% |
| 24.1% | 12.0% | 16.1% | 19.8% | 23.0% | 25.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (26)
- News (RSS)seekingalpha·just now·Neutral
IQVIA nears $1.1B acquisition of UK's Quotient Sciences - Bloomberg
View source ↗ - News (RSS)zerohedge·3d ago·Negative
…emen - companies and research networks that extract, process, and package medical records into datasets for researchers to analyze.Commercial data companies, such as IQVIA, TriNetX and Merative, along with research networks such as OHDSI and PEDSnet, now occupy this space.They largely draw on real patient data from electronic health records, Medicare, insurance claims, and other healthcare databases.But some, such as OHDSI, can also work with synthetic data - artificially generated patient recor…
View source ↗ - Newszacks.com·9d ago·Positive
IQVIA Stock Jumps 59% in 6 Months: Here's What You Should Know IQV's growth is fueled by rising clinical research demand, strong commercial services momentum, AI adoption and operational efficiencies that boost profitability.
View source ↗ - Newsfool.com·13d ago·Positive
IQVIA: 3 Key Takeaways for Long-Term Investors Net new clinical bookings reached $3.2 billion in the third quarter. Last 12-month net new bookings increased 14% to $11.7 billion.
View source ↗ - Newszacks.com·24d ago·Positive
Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsmarketbeat.com·26d ago·Positive
What IQVIA (IQV) Said on Its Q3 Earnings Call IQVIA NYSE: IQV reported third-quarter results that exceeded the high end of its guidance ranges, supported by accelerating organic growth in its Commercial Solutions and R&D Solutions businesses, higher clinical win rates and strong free cash flow.
View source ↗ - News (RSS)seekingalpha·26d ago·Neutral
IQVIA Holdings Inc. 2026 Q3 - Results - Earnings Call Presentation
View source ↗ - News (RSS)investing·26d ago·Neutral
IQVIA Q3 2026 slides: double-digit EPS growth, raised outlook
View source ↗ - Newszacks.com·26d ago·Positive
IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y IQV's Q3'26 earnings beat estimates as revenues rise 8% y/y, led by strong clinical demand, robust R&D bookings and improved execution, prompting a view hike.
View source ↗ - Newszacks.com·26d ago·Positive
IQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue Estimates IQVIA Holdings (IQV) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.24 per share. This compares to earnings of $3 per share a year ago.
View source ↗ - Newszacks.com·31d ago·Positive
IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know IQV is poised for y/y revenue and earnings growth in Q3, driven by stronger clinical research demand, solid bookings, AI adoption and operational efficiencies.
View source ↗ - Newszacks.com·45d ago·Positive
Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·51d ago·Positive
Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.
View source ↗ - News (Marketaux)gurufocus.com·59d ago·Negative
IQVIA Holdings (IQV) Completes $2 Billion Senior Notes Offering to Refinance Debt IQVIA Holdings Inc[+304 characters]
View source ↗ - Newszacks.com·67d ago·Neutral
IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.
View source ↗ - News (RSS)investing·68d ago·Neutral
IQVIA Holdings stock hits 52-week high at 271.82 USD
View source ↗ - News (RSS)yahoo·68d ago·Positive
A Strong Rebound Case of IQVIA Holdings (IQV)
View source ↗ - Newszacks.com·72d ago·Positive
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - News (RSS)yahoo·73d ago·Positive
IQVIA Holdings Stock: Is IQV Outperforming the Health Care Sector?
View source ↗ - News (RSS)seekingalpha·74d ago·Neutral
IQVIA prices $2B of senior notes due 2034
View source ↗ - News (Marketaux)gurufocus.com·78d ago·Positive
IQVIA (IQV) Insider James Berkshire Sells 2,668 Shares James Berkshire, an insider at IQVIA[+222 characters]
View source ↗ - News (RSS)investing·80d ago·Neutral
IQVIA launches AI platform for clinical trial development
View source ↗ - News (RSS)investing·81d ago·Neutral
IQVIA stock hits 52-week high at 265.29 USD
View source ↗ - Newszacks.com·87d ago·Neutral
Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report? IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·88d ago·Positive
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.
View source ↗ - Newszacks.com·102d ago·Positive
IQV Stock Gains 42% in 3 Months: Here's What You Should Know IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.
View source ↗
Earnings
Thu, Feb 4(in 2 months)
Consensus estimate $3.60 per share
Typical surprise +2.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Oct 27$3.34 vs $3.26beat
- Tue, Jul 28$3.15 vs $3.03beat
- Tue, May 5$2.90 vs $2.82beat
- Thu, Feb 5$3.42 vs $3.40beat
- Tue, Oct 28$3.00 vs $2.98beat
- Tue, Jul 22$2.81 vs $2.77beat
Estimates and results for IQV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IQV officers and directors.
- Bought
- —
- Sold
- $31.1m
0 trades
10 trades
- Sherbet Ericsold
- Berkshire James G.sold
- Staub W Richardsold
- Patel Bhaviksold
- Sherbet Ericsold
- Cherofsky Keriannsold
- Bousbib Arisold
- Bousbib Arisold
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (20d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (14d later)Sell$15,001 - $50,000
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (25d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (20d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (25d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Apr 6, 2026 (21d later)Sell$50,001 - $100,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Markwayne Mullinsenate · OK · disclosed Jan 16, 2026 (18d later)Buy$15,001 - $50,000
- John Boozmansenate · AR · disclosed Nov 15, 2025 (44d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 2, 2025 (18d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Buy$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Sell$1,001 - $15,000
- Markwayne Mullinsenate · OK · disclosed Feb 27, 2025 (14d later)Buy$15,001 - $50,000
- Markwayne Mullinsenate · OK · disclosed Sep 19, 2024 (30d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (8d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (20d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
